IMPORTANT: Read the Prep & Administration Guide for proper handling, reconstitution (if applicable), and administration technique. Mistakes here can compromise your research.
Tirzepatide is an incretin-based peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It has been studied extensively in clinical trials for type 2 diabetes and obesity, demonstrating substantial improvements in glycemic control and significant weight loss.
— 5 mg Vial —
Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 28 days.
Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Frequency: Inject once weekly subcutaneously on the same day each week. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 units (1.0 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 100 units (1.0 mL) × 2 injections |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) × 3 injections |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 4 injections |
— 10 mg Vial —
Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).
Easy measuring: At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 28 days.
Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Frequency: Inject once weekly subcutaneously on the same day each week. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 50 units (0.50 mL) |
| Weeks 5–8 | 5 mg | 100 units (1.0 mL) |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) × 2 injections |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 2 injections |
— 15 mg Vial —
Reconstitute: Add 2.0 mL bacteriostatic water → 7.5 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).
Easy measuring: At 7.5 mg/mL, 1 unit = 0.01 mL = 75 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 28 days.
Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Frequency: Inject once weekly subcutaneously on the same day each week. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 33 units (0.33 mL) |
| Weeks 5–8 | 5 mg | 67 units (0.67 mL) |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) |
| Weeks 13–16 | 10 mg | 67 units (0.67 mL) × 2 injections |
— 30 mg Vial —
Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 28 days.
Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Frequency: Inject once weekly subcutaneously on the same day each week. All doses fit in a single 1 mL insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 units (0.25 mL) |
| Weeks 5–8 | 5 mg | 50 units (0.50 mL) |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) |
— 30 mg Vial —
Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).
Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 28 days.
Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Frequency: Inject once weekly subcutaneously on the same day each week. All doses fit in a single 1 mL insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 25 units (0.25 mL) |
| Weeks 5–8 | 5 mg | 50 units (0.50 mL) |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) |
- Large reductions in HbA1c in type 2 diabetes (clinical trials).
- Significant weight loss and waist circumference reduction (clinical trials).
- Improved fasting glucose and insulin sensitivity markers.
- Improvements in blood pressure and lipid parameters in many trial populations.
- Reduced appetite and caloric intake via central satiety signaling and slowed gastric emptying.
Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 receptor agonism increases glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying, and reduces appetite. GIP receptor agonism can further enhance insulin secretion and may have complementary effects on adipose tissue and energy balance.
Potential adverse effects reported in literature and/or anecdotally include:
- Nausea.
- Vomiting.
- Diarrhea or constipation.
- Decreased appetite.
- GERD-like symptoms/abdominal discomfort.
- Injection-site reactions.
- Rare: pancreatitis (class-associated signal).
- Gallbladder events with rapid weight loss (class-associated).
- Titrate gradually to improve GI tolerability.
- Eat smaller, lower-fat meals during escalation.
- Maintain hydration/electrolytes if GI upset occurs.
- Hold dose escalation or reduce dose if symptoms persist.
- Stop and seek evaluation for severe abdominal pain (pancreatitis/gallbladder warning sign).
PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).
- Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID: 35658024 (doi: 10.1056/NEJMoa2206038)
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. PMID: 34170647 (doi: 10.1056/NEJMoa2107519)
- Dual incretin (GIP/GLP-1) receptor agonism: mechanisms and translational considerations (review). Nat Rev Endocrinol. PubMed
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).